A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells

CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare it...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: DiLillo, David J., Olson, Kara, Mohrs, Katja, Meagher, Thomas Craig, Bray, Kevin, Sineshchekova, Olga, Startz, Thomas, Kuhnert, Jessica, Retter, Marc W., Godin, Stephen, Sharma, Prachi, Delfino, Frank, Lin, John, Smith, Eric, Thurston, Gavin, Kirshner, Jessica R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948265/
https://ncbi.nlm.nih.gov/pubmed/33651100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002736
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados